ChemoCentryx fourth quarter revenues increase to $26.1 million

ChemoCentryx, Inc.Mar 31 2012

ChemoCentryx, Inc. (NASDAQ: CCXI) announced today its financial results for the fourth quarter and year ended December 31, 2011. Net income for the fourth quarter ended December 31, 2011 was $18.2 million compared to $5.1 million during the same quarter in 2010.  Net loss for the year ended December 31, 2011 was $4.6 million compared to $3.1 million for the year ended December 31, 2010. Cash, cash equivalents and investments totaled $96.1 million at December 31, 2011, compared to $82.8 million at December 31, 2010.

"The continued advancement of our broad pipeline in 2011 put us in a strong strategic position for the successful completion of the Company's recent initial public offering," said Thomas J. Schall, Ph.D., President and Chief Executive Officer, ChemoCentryx.  "Our financial strength gives us the independence to develop and commercialize CCX140 for chronic kidney disease in North America, the program leading our forward integration plan.  We look forward to advancing our experimental medicines currently in clinical trials as well as our other promising new drug candidates targeting the chemokine system."

2011 Highlights and Recent Developments

Clinical

• Traficet-EN (vercirnon) — The Company's most advanced drug candidate is currently in Phase III clinical development, conducted by partner GlaxoSmithKline (GSK) for the treatment of patients with moderate-to-severe Crohn's disease:
  • Initiated four pivotal Phase III clinical trials in patients with moderate-to-severe Crohn's disease.
• CCX140 — The Company's lead independent drug candidate, currently in Phase II clinical development for the treatment of diabetic nephropathy:
  • Successfully completed a Phase II clinical trial in type 2 diabetics as a gateway study to initiating two Phase II clinical trials in patients with diabetic nephropathy in December 2011.
• CCX354 – The Company's CCR1 inhibitor which successfully completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis:
• In November 2011, GSK exercised its option to obtain an exclusive license for the further development and commercialization of the drug candidate, for which the Company received $25.0 million.

Recent Developments and Anticipated Milestones in 2012

• Successfully completed an initial public offering and concurrent private placements in February 2012, through which gross proceeds of $63.7 million were generated;
• Completion of enrollment and dosing of the original 135 patient cohort in the adaptive trial design of the ongoing Phase II clinical trial of CCX140 in diabetic nephropathy;
• Enrollment of a Phase II clinical trial for CCX168 for ANCA-Associated Vasculitis is expected to complete by the end of 2012;
• Initiation of a Phase I clinical trial for at least one of the following two programs:
• CCX872, the Company's next generation CCR2 inhibitor for the treatment of metabolic diseases; or
• CCX507, the Company's next generation CCR9 inhibitor for the treatment of inflammatory bowel disease.

Selected Fourth Quarter and Full Year 2011 Financial Results

Revenues for the fourth quarter ended December 31, 2011 were $26.1 million, compared to $13.1 million for the same period in 2010. The increase was due to the $25.0 million option exercise fee received from GSK in 2011 for the exclusive license to further develop and commercialize CCX354, our CCR1 inhibitor.  Partially offsetting the 2011 increase was $10.0 million in milestones recognized in 2010.  Revenues for the year ended December 31, 2011 were $31.7 million, compared to $34.9 million in 2010. The decrease in revenue was primarily due to lower funding of non-clinical support from GSK for CCX168 and the ChemR23 research program in 2011.

Research and development expenses for the fourth quarter 2011 were $5.4 million compared to $8.1 million for the same period in 2010. Research and development expenses for the year ended December 31, 2011 were $28.4 million compared to $33.5 million in 2010. The decrease was primarily due to the completion of the Phase II clinical trial for CCX354 in 2011.

General and administrative expenses for the fourth quarter of 2011 were $1.9 million and the same for the comparable period in 2010. General and administrative expenses for the year ended December 31, 2011 were $7.6 million compared to $7.3 million for 2010.

Cash, cash equivalents and investments totaled $96.1 million at December 31, 2011, compared to $82.8 million at December 31, 2010.

2012 Financial Outlook

Projected 2012 year-end cash, cash equivalents and investments is expected to be at least $115.0 million.